April 11, 2019 08:24 AM EDT
R&D
Pharma

Re­gen­eron, Al­ny­lam spell out a re­search al­liance that could run be­yond a decade, with bil­lions built in for suc­cess

John Carroll

Editor & Founder

Re­gen­eron $REGN and Al­ny­lam $AL­NY have laid a foun­da­tion for an en­dur­ing R&D al­liance that could go out well past a decade, with bil­lions of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

FDA re­jects Dai­ichi Sanky­o's HER3 ADC, a blow to quick ap­proval plans for Mer­ck part­ner­ship

Grail pi­o­neered mul­ti-can­cer tests. But the com­pa­ny’s rough pub­lic de­but shows the in­dus­try could be in trou­ble

What Co­herus' $40M sale of its Hu­mi­ra biosim­i­lar says about the crowd­ed mar­ket

To tack­le a dead­ly brain dis­ease, sci­en­tists de­vise small but charm­ing epi­ge­net­ic edit­ing tool

Bio­gen is pur­su­ing more deal­mak­ing this year, with plans to spend up to $8B

A service from the Financial Times